Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 35 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

34%

12 trials in Phase 3/4

Results Transparency

0%

0 of 9 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

25Total
Not Applicable (6)
Early P 1 (1)
P 1 (3)
P 2 (3)
P 3 (8)
P 4 (4)

Trial Status

Completed9
Recruiting9
Not Yet Recruiting8
Unknown7
Withdrawn1
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 9 completed trials

Clinical Trials (35)

Showing 20 of 20 trials
NCT07809477Not ApplicableNot Yet Recruiting

Integrated Diabetes and Oral Health Care in Oman

NCT07795918Not Yet Recruiting

PREDICT-DM: Community Pharmacy-Based Point-of-Care Testing for Undiagnosed T2DM

NCT07005362Completed

Fitbit and AI Chatbot in Sedentary Primary Care Patients With T2D

NCT07527650Phase 2Recruiting

Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus

NCT07148713Not ApplicableActive Not Recruiting

Pilot of Continuous Glucose Monitor-Augmented Food Is Medicine

NCT07599410Phase 2RecruitingPrimary

A Research Study to Investigate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes Mellitus

NCT07496177Phase 2RecruitingPrimary

A Mechanistic Study on the Effect of HTD1801 Versus Placebo on Kidney Function in Patients With Type 2 Diabetes and Chronic Kidney Disease.

NCT07486986Not Yet Recruiting

Endocrine Disruption, Menopause, and Poor Sleep in wOmen With Type 2 Diabetes: Effects on Cardiovascular Health

NCT06571591Phase 3CompletedPrimary

Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin

NCT07289750Phase 4Not Yet RecruitingPrimary

The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD

NCT07421921Completed

Detecting Type 2 Diabetes From Voice

NCT07347080Early Phase 1Not Yet RecruitingPrimary

A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus

NCT06942195Not ApplicableRecruitingPrimary

Effects of Calcium on Gut Functions and Blood Glucose in Humans With Type 2 Diabetes

NCT07183137Completed

Metabolic Surgery for Metabolic Syndrome

NCT07165158Phase 4Not Yet Recruiting

The Effect of Semaglutide on Bone Health

NCT05680155Phase 3CompletedPrimary

A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients

NCT07139535Phase 3Not Yet RecruitingPrimary

A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

NCT07139548Phase 3Not Yet RecruitingPrimary

A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes

NCT07093476Phase 3RecruitingPrimary

Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin

NCT07019012Phase 4RecruitingPrimary

Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.

Scroll to load more

Research Network

Activity Timeline